WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the resignation of FDA Commissioner Marty Makary.
“Dr. Makary inherited an FDA in crisis after the DOGE changes, which included the firing of thousands of employees. These staffing and morale challenges were compounded by constant leadership changes over the past year and questions around shifting FDA standards for drug approvals. What we need now is strong, stable and science-driven leadership at the FDA. We are losing the biotech race with China. FDA must be strengthened immediately to ensure that patients continue to benefit from medical miracles and that the United States leads the world in biomedical innovation, which is crucial for the public health, economic growth and our national security.”